Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Stomach Neoplasms 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Locally Advanced Cervical Carcinoma 1Liver Neoplasms 1Liver Diseases 1HR+ Breast Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Colorectal Carcinoma 1

Interventions

Blood Specimen Collection 2toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1lenvatinib 1gadolinium ethoxybenzyl DTPA 1camrelizumab 1User-Centered Design 1Standard of Care 1Shadowing Technique, Histology 1Nivolumab 1Neuropsychological Tests 1Lead 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Liver Diseases × sintilimab × Clear all
NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Sun Yat-sen University

Completed
600 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡